<DOC>
	<DOCNO>NCT02165033</DOCNO>
	<brief_summary>Budesonide + Procaterol HFA MDI novel asthma product contain budesonide procaterol single inhaler . Budesonide corticosteroid treat underlie airway inflammation asthma . Procaterol direct act sympathomimetic predominantly Beta-adrenoceptor stimulant activity selective Beta-2 receptor ( Beta-2 agonist ) . It use bronchodilator management reversible airway obstructive pulmonary disease . Budesonide Procaterol therefore complementary effect , treat two different component asthma .</brief_summary>
	<brief_title>Multiple-dose Pharmacokinetics Study `` SYN006 HFA MDI '' Administered Orally Healthy Volunteers</brief_title>
	<detailed_description>Test drug : SYN006 HFA MDI Batch No : BPP-033-088 Dosage Form : HFA Metered Dose Inhaler Active Substance : Budesonide 180ug procaterol hydrochloride hydrate 10ug/dose Dosage regimen : Multiple dose ( 4 puff : budesonide 720ug procaterol hydrochloride hydrate 40ug ) ; thirteen consecutive dos</detailed_description>
	<mesh_term>Procaterol</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Provision sign write informed consent enrollment study , ability communicate investigator , understand comply requirement study . Healthy adult , age 20 40 year old . Subjects Body Mass Index ( BMI ) &gt; =18.5 &lt; =25.0 ( BMI calculate weight kilogram [ kg ] /height meters2 [ m2 ] ) . Physically mentally healthy subject confirm interview , medical history , clinical examination , chest xray electrocardiogram . Clinical laboratory test : within limit normal range acceptable investigator . History drug alcohol abuse within past year . Medical history severe drug allergy sensitivity analogous drug . Evidence acute chronic disease undergo surgery 4 week prior Period I dose . Evidence clinical significant renal , cardiovascular , hepatic , hematopoietic , neurological , pulmonary gastrointestinal pathology . Creatinine &gt; 2UNL ( upper normal limit ) ; Liver enzymes &gt; 2UNL ; Total bilirubin &gt; 2UNL . Planned vaccination time course study . Taking clinical investigation drug 2 month prior Period I dose . Use medication , include herb medicine 4 week dose . Donation 500mL blood past 3 month prior dose donation 250mL blood past 2 month prior dose . A positive Hepatitis B surface antigen positive Hepatitis C antibody result . A positive test HIV antibody . In screen subject give train ensure subject able correctly use investigational product . If subject , use investigational product lack proficiency include study . Students National Defense Medical Center . For female subject , meet follow criterion : 1 . Lactating woman 2 . Positive pregnancy test ( urine ) screening , prior dose 3 . Do use adequate contraception study 4 . Women take oral contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>